Goldman Sachs Group began coverage on shares of LifePoint Health (NASDAQ:LPNT) in a report published on Wednesday, Marketbeat Ratings reports. The brokerage issued a sell rating and a $45.00 price objective on the stock.

LPNT has been the subject of several other reports. Mizuho set a $50.00 target price on LifePoint Health and gave the stock a hold rating in a research note on Friday, October 27th. BidaskClub upgraded LifePoint Health from a strong sell rating to a sell rating in a research note on Friday, December 15th. ValuEngine cut LifePoint Health from a buy rating to a hold rating in a research note on Sunday, December 31st. Credit Suisse Group assumed coverage on LifePoint Health in a research note on Thursday, November 2nd. They set a neutral rating and a $54.00 target price for the company. Finally, Zacks Investment Research cut LifePoint Health from a hold rating to a sell rating in a research note on Tuesday, October 3rd. Three research analysts have rated the stock with a sell rating, twelve have given a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of $59.14.

Shares of LifePoint Health (LPNT) opened at $47.55 on Wednesday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.65 and a current ratio of 1.85. LifePoint Health has a 12-month low of $42.50 and a 12-month high of $70.95. The stock has a market capitalization of $1,891.96, a P/E ratio of 12.24, a P/E/G ratio of 1.13 and a beta of 0.67.

LifePoint Health (NASDAQ:LPNT) last released its earnings results on Friday, October 27th. The company reported $0.80 earnings per share for the quarter, missing the consensus estimate of $0.95 by ($0.15). LifePoint Health had a return on equity of 7.01% and a net margin of 2.45%. The business had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.60 billion. During the same quarter in the previous year, the company earned $0.94 earnings per share. The firm’s revenue for the quarter was down .7% on a year-over-year basis. analysts forecast that LifePoint Health will post 3.64 EPS for the current fiscal year.

LifePoint Health declared that its Board of Directors has approved a share buyback plan on Friday, October 27th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to purchase shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its shares are undervalued.

In other news, Director Marguerite Kondracke sold 3,416 shares of the stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $43.80, for a total value of $149,620.80. Following the completion of the transaction, the director now directly owns 17,479 shares in the company, valued at approximately $765,580.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.76% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Public Employees Retirement System of Ohio lifted its stake in shares of LifePoint Health by 20.8% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 15,429 shares of the company’s stock valued at $893,000 after acquiring an additional 2,660 shares during the last quarter. California Public Employees Retirement System lifted its stake in shares of LifePoint Health by 4.4% in the 3rd quarter. California Public Employees Retirement System now owns 186,689 shares of the company’s stock valued at $10,809,000 after acquiring an additional 7,903 shares during the last quarter. Convergence Investment Partners LLC bought a new position in shares of LifePoint Health in the 3rd quarter valued at $811,000. OxFORD Asset Management LLP bought a new position in shares of LifePoint Health in the 3rd quarter valued at $303,000. Finally, Schwab Charles Investment Management Inc. lifted its stake in shares of LifePoint Health by 7.8% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 148,762 shares of the company’s stock valued at $8,614,000 after acquiring an additional 10,757 shares during the last quarter. Institutional investors own 99.18% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.watchlistnews.com/lifepoint-health-lpnt-earns-sell-rating-from-analysts-at-goldman-sachs-group/1797273.html.

LifePoint Health Company Profile

LifePoint Health, Inc, through its subsidiaries, owns and operates community hospitals, regional health systems, physician practices, outpatient centers and post-acute facilities. As of December 31, 2016, the Company operated 72 hospital campuses in 22 states, having a total of 9,424 licensed beds. It offers a range of general and specialized healthcare services to patients through a network of hospitals and outpatient facilities.

Analyst Recommendations for LifePoint Health (NASDAQ:LPNT)

Receive News & Ratings for LifePoint Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifePoint Health and related companies with Analyst Ratings Network's FREE daily email newsletter.